Clinical Trials Update: June 5, 2009

-- Here are the latest clinical trials, courtesy of CenterWatch and ClinicalConnection.com:

Cardiac Surgery

If you are an adult planning to have a cardiac surgical procedure, you may qualify for this study.

The research site is in Bismarck, N.D.

More information

Please see http://www.centerwatch.com/clinical-trials/listings/studylist.aspx?CatID=351.

-----

Attention Deficit/Hyperactivity Disorder (ADHD - Adults)

If you are an adult with attention deficit/hyperactivity disorder, you may qualify for this study.

The research site is in Seattle, Wash.

More information

Please see http://www.centerwatch.com/clinical-trials/listings/studylist.aspx?CatID=499.

-----

Depression

If you are an adult with depression, you may qualify for this study.

The research site is in Portland, Ore.

More information

Please see http://www.centerwatch.com/clinical-trials/listings/studylist.aspx?CatID=164.

-----

Migraine

This study is to evaluate the effectiveness and tolerability of rizatriptan (Maxalt) to treat acute migraines in people who don't respond to sumatriptan (Imitrex) .

The research site is in Charleston, S.C.

More information

Please see http://www.clinicalconnection.com/clinical_trials/condition/migraine.aspx.

-----

Type 2 Diabetes

This study is for type 2 diabetics whose current medication is insufficient. Participants will receive study related medication or placebo, physical exam, lab test, diet counseling, and reimbursement for time and travel expenses.

The research site is in Lakewood, Wash.

More information

Please see http://www.clinicalconnection.com/clinical_trials/condition/diabetes.aspx.

-----

Osteoarthritis of the Hip

This study is for people with osteoarthritis of the hip.

The research site is in Cincinnati, Ohio.

More information

Please see http://www.clinicalconnection.com/clinical_trials/condition/osteoarthritis.aspx.

-----

Copyright 2009 CenterWatch and ClinicalConnection.com. All rights reserved.

Posted: June 2009


View comments

Hide
(web3)